New York-based Provista Diagnostics will this month launch a prospective clinical study for its protein biomarker-based breast cancer diagnostic, DtectDx Breast, and could submit a 510(k) for the test to the US Food and Drug Administration sometime this year, CEO David Reese told ProteoMonitor this week.

The company also this month expanded its contract research business, adding to the services offered out of its Scottsdale, Ariz.-based CLIA-certified, GLP-capable laboratory.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.